| |
Innovative immune therapy advancements don't just happen anywhere. Discover why the industry's leaders choose Puerto Rico to impact the world. It's not what's next, it's where. 
|
|
Today’s Big NewsMar 26, 2024 |
| By Fraiser Kansteiner The Biden Administration and mifepristone’s manufacturer, Danco Laboratories, are getting their day in court, as they attempt to fight one of the most pivotal battles surrounding reproductive health since the Supreme Court overturned Roe v. Wade in 2022. |
|
|
|
By Max Bayer Moderna's next-gen COVID vaccine beat its approved counterpart in phase 3, boasting a stronger immune response. The new data is critical to Moderna's combo ambitions. |
By Angus Liu The CEOs of AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Novartis, Pfizer and Takeda came together in Beijing to show the companies’ continued interest in China and to offer their advice for the country’s healthcare industry. |
By Conor Hale The Bluetooth-equipped Assert-IQ Is designed to record irregular heartbeats—including hard-to-catch cases of atrial fibrillation—and alert clinicians to the data necessary for choosing the optimal course of treatment. |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
By Gabrielle Masson Nanoscope Therapeutics is back with more data assessing its gene therapy that uses light-sensitive molecules to treat retinal disease. With data demonstrating vision improvement in hand, the biotech is now planning to submit the therapy for FDA approval later this year. |
By Annalee Armstrong,James Waldron Investors are stocking up on Stoke Therapeutics, sending the biotech’s shares jumping over 90% in pre-market trading on the back of positive phase 1/2a data for a seizure disorder medicine. |
By Andrea Park Just a few months after earning FDA approval for Voquezna in erosive esophagitis and associated heartburn, Phathom Pharmaceuticals has launched its first-ever full-scale DTC campaign to support the indication. |
By Zoey Becker The state's new Prescription Drug Affordability Review Board voted to subject the blockbuster arthritis med to an upper price limit, which Amgen calls a violation of the company's constitutional rights. |
By James Waldron With its sole remaining asset having failed to even enter the clinic, Ampio Pharmaceuticals has decided to call it a day. |
By Conor Hale The drug-free approach uses magnetic coils to generate pulses that aim to restart dormant synapse pathways in brain regions that help govern mood. |
By Andrea Park It’s no mystery who’s responsible for the first-ever billboards in the U.S. to show a vibrator. |
By Kevin Dunleavy While bluebird bio reported details on the progress of its launch of three gene therapies on Tuesday, the Massachusetts biotech also said it will have to refile its financial statements from 2022 and the first three quarters of 2023 because of accounting errors. |
By James Waldron Novo Nordisk may be racing to get an oral successor to its Wegovy weight loss sensation through clinical trials, but Viking Therapeutics is sailing up close behind. |
By Andrea Park No run-of-the-mill desk workers here—AbbVie’s trio of “Just Okay” TV commercials for Rinvoq’s arthritis indications focus on individuals performing jobs typically reserved for a quirky lead in a romantic comedy. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we explore the European biotech investment landscape. Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector. |
|
|---|
|
|
|
Thursday, April 11, 2024 | 11am ET / 8am PT As clinical trials increase in complexity, drug developers face growing pressure to deliver on-time, on-budget studies. FSP partnerships have emerged as a pivotal strategy to help address current challenges. Join us to learn moreas we explore the findings of The 2024 FSP Trends Report from the PPD clinical research business of Thermo Fisher Scientific. Sign up now! 
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
